PolyPeptide Group AG's Total Assets for the quarter that ended in Dec. 2025 was $967.2 Mil.
Warning Sign:
If a company builds assets at 11.8% a year, faster than its revenue growth rate of 5.2% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, PolyPeptide Group AG's average Total Assets Growth Rate was 9.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 9.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 11.80% per year.
During the past 8 years, PolyPeptide Group AG's highest 3-Year average Total Assets Growth Rate was 19.10%. The lowest was 9.70%. And the median was 13.00%.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
PolyPeptide Group AG's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
PolyPeptide Group AG Total Assets Related Terms
PolyPeptide Group AG Total Assets Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
PolyPeptide Group AG's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (PLYGF) has a Total Assets of $967.2 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Total Assets too high?
PolyPeptide Group AG's current Total Assets is $967.2 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Total Assets compare to ZTS and UTHR?
PolyPeptide Group AG's Total Assets of $967.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Total Assets is $967.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.83, compared to a current price of $43.00 — trading 60.3% above its estimated fair value. The current Total Assets is $967.2 Mil. PolyPeptide Group AG's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Total Assets is $967.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $43.00 is trading 60.3% above its estimated GF Value™ of $26.83.
GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.
Key valuation signals for PLYGF:
Total Assets: $967.2 Mil
GF Value™: $26.83 vs. price of $43.00 (60.3% above fair value)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
56GF Score
Get the complete analysis for PLYGF
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
